Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study

Abusnana, Salah; Awadi, Fatheya Al; Aly, Hazem; Bashier, Alaaeldin; Dhanwal, Dinesh; Halasa, Tariq Hisham Beshara; Jallo, Mahir; Medina, Johan; Singhal, Sagar

doi:10.1016/j.diabres.2022.110183

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from several real‐world studies support the results obtained in the IDegLira DUAL programme, highlighting the generalizability of the clinical trial results to routine practice and providing important, country‐specific clinical evidence 14–22 . The European multicentre real‐world retrospective study EXTRA showed significant reductions in HbA1c and body weight after ≥6 months of treatment with IDegLira in patients coming from a multiple daily‐dose insulin injection regimen 23 …”

Section: Introductionmentioning

confidence: 75%

“…13 Data from several real-world studies support the results obtained in the IDegLira DUAL programme, highlighting the generalizability of the clinical trial results to routine practice and providing important, country-specific clinical evidence. [14][15][16][17][18][19][20][21][22] The European multicentre real-world retrospective study EXTRA showed significant reductions in HbA1c and body weight after ≥6 months of treatment with IDe-gLira in patients coming from a multiple daily-dose insulin injection regimen. 23 The scientific community and regulatory agencies are interestingly appreciating the potential of real-world studies as a source to support decision-making on the benefits and risks associated with clinical interventions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

IDegLira for the real‐world treatment of type 2 diabetes in Italy. Final results from the REX observational study

Fadini,

Buzzetti,

Pitocco

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimThe study was designed to generate real‐world evidence on IDegLira in the Italian clinical practice in two groups of patients with type 2 diabetes (T2D), switching to IDegLira either from a basal only (basal group) or basal‐bolus insulin regimen (BB group).Materials and MethodsThis was a non‐interventional, multicentre, single‐cohort, prospective study assessing the long‐term glycaemic control in patients with T2D, who switched to IDegLira from a basal insulin ± glucose‐lowering medication regimen with or without a bolus insulin component for approximately 18 months, conducted in 28 Italian diabetes centres. The primary endpoint was the change in glycated haemoglobin (HbA1c) levels from baseline to 6 months after IDegLira initiation.ResultsThe study included 358 patients with a mean age 67.2 years and diabetes duration of 15.7 years. HbA1c significantly decreased from IDegLira start to all study time points in the overall population (basal group −1.19%; BB group −0.60% at the end of observation). Patients achieving HbA1c <7% levels increased from 12.9% (n = 43) to 40.3% (n = 110) at 18 months. Fasting blood glucose and body weight also significantly decreased in both groups, although more in the BB group. Overall, 14.3% of completed patients had an intensification of treatment (mainly in the basal group) and 48.6% had a simplification of treatment (mainly in the BB group).ConclusionsSwitching to IDegLira in a real‐world clinical setting is a valid therapeutic option for patients with T2D with inadequate glycaemic control on basal or BB insulin regimen and/or need to simplify their insulin therapy, with specific reasons and therapeutic goals according to different T2D management trajectories.

show abstract

Section: Introductionmentioning

confidence: 75%

Section: Introductionmentioning

confidence: 99%

IDegLira for the real‐world treatment of type 2 diabetes in Italy. Final results from the REX observational study

Fadini,

Buzzetti,

Pitocco

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Insulin degludec/liraglutide

2023

Reactions Weekly

View full text Add to dashboard Cite

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The May 2017 monograph topics are brodalumab, etelcalcetide, guselkumab, ribociclib, and sirukumab. The MUE is on ribociclib.

show abstract

Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study

Cited by 2 publications

References 30 publications

IDegLira for the real‐world treatment of type 2 diabetes in Italy. Final results from the REX observational study

IDegLira for the real‐world treatment of type 2 diabetes in Italy. Final results from the REX observational study

Insulin degludec/liraglutide

Contact Info

Product

Resources

About